Abstract
In this study, a rationally designed nanocomposite (BUDPDA@MAP) composed of polydopamine (PDA) nanoparticle and anti‐inflammatory drug budesonide (BUD) encapsulated in a pH‐responsive endosomolytic polymer (poly(butyl methacrylate‐co‐methacrylic acid) grafted acetalated dextran, denoted by MAP), is proposed. The uniform nanocomposite is prepared using a microfluidic device. At low endosomal pH (5.5), MAP destabilizes the endosomal membranes for the cytoplasmic delivery of PDA, and releases BUD simultaneously, resulting in a greater reactive oxygen species scavenging capability than both the free drug and PDA alone. The combined therapeutic efficacy from PDA and BUD also leads to a successful macrophage phenotype switch from pro‐inflammatory M1 to anti‐inflammatory M2.
Original language | English |
---|---|
Article number | 2000058 |
Journal | Advanced Therapeutics |
Volume | 4 |
Issue number | 1 |
Number of pages | 11 |
ISSN | 2366-3987 |
DOIs | |
Publication status | Published - Jan 2021 |
MoE publication type | A1 Journal article-refereed |
Fields of Science
- ANTIGEN
- ENHANCEMENT
- INFLAMMATION
- NANOPARTICLES
- PEPTIDES
- POLYMERS
- drug delivery
- endosomal escape
- macrophage phenotypes
- microfluidics
- polydopamine
- 317 Pharmacy
- 221 Nano-technology
- 318 Medical biotechnology